Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hey roger watch rgno today,, news should be out and we will see the next stop at 11 cents good luck to all hope everyone had a happy fathers day
re: IDGI
after 2 r/s float is approx 248k
(Stacy Josloff btw is (was?) married to Donny Deutsch, host of CNBC’s “The Big Idea.
just found this news...
INCA Designs, Inc. Acquires High Fashion Design Company
NEW YORK, Jun 08, 2007 (BUSINESS WIRE) -- INCA Designs, Inc. (Pink Sheets:IDGI), formerly known as Transportation Safety Technology, Inc., changed its name to INCA Designs, Inc. in April in anticipation of closing the acquisition of S2 New York Design Corp., the owner of the popular INCA line of bags, swimwear, and resort wear. In conjunction with the acquisition that closed on May 31, 2007, the Company reconstituted its Board of Directors and named new officers.
Stacy Josloff and Stephanie Hirsch serve as the Company's Board of Directors. Josloff serves as the Company's Chief Executive Officer and Chief Financial Officer and Hirsch serves as President and Secretary.
Stephanie Hirsch, a world traveler with a free spirit and creative mind, launched INCA in 1998 upon her return from hiking the Inca Trail in Peru. Inspired by the memories of her travels, she created INCA, which began as a line of handbags. After the handbags became an instant hit with Hollywood celebrities, Hirsch explored new horizons and created a line of sexy, fun swimwear and a sophisticated selection of matching cover-ups and resort wear that echoed the vibe of the INCA handbags.
Hirsch then teamed up with Stacy Josloff, who had spent ten years as a high profile sales executive at Ralph Lauren (Black and Purple Label) and Max Mara. Josloff focuses on business strategy, marketing, sales, and merchandising while Hirsch concentrates on design, public relations and production, adding new pieces to merchandise and mix and match to the collection every day.
The INCA line currently includes inca, incagirl, and inca accessories (pillows, towels, tabletop). Plans for expanding the INCA line include a boy's line (inca jr.), home accessories, 'and everything in between', says Hirsch. "We have set our sights on a new destination: full lifestyle brand development and major company expansion," says Hirsch.
Since 1998, INCA has been featured in major trend-setting magazines, including Vogue, Harper's Bazaar, Glamour, Allure, Lucky, Marie Claire, Cosmopolitan, Oprah, and Sports Illustrated Swimsuit issue (where INCA graced four pages of the special issue). INCA has been seen on national television on Good Morning America, The Oprah Winfrey Show, and MTV's House of Style. INCA is available at the best stores and specialty boutiques such as Barney's, NY; Bergdorf Goodman, NY; Scoop, NY; Fred Segal, CA; and Jill Roberts, CA.
Corporate offices are located at 53 W. 36th Street, Suite 906, New York, NY 10018. Questions should be directed to Stacy Josloff, CEO at 212-967-5212 or may be emailed to info@incagirl.com. More information about the Company is available on the Company's website at www.incagirl.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of INCA Designs, Inc. Certain statements in this release and other written or oral statements made by or on behalf of the Company are "forward looking statements" within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. The forward looking statements are subject to a number of risks and uncertainties including market acceptance of the Company's services and projects and the Company's continued access to capital and other risks and uncertainties. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.
SOURCE: INCA Designs, Inc.
CONTACT: INCA Designs, Inc., New York
Stacy Josloff, CEO, 212-967-5212
info@incagirl.com
www.incagirl.com
Copyright Business Wire 2007
funny Johno...and g'mornin
LOL ! This is right up your alley ! A feast of burgernomics !
http://www.investorshub.com/boards/read_msg.asp?message_id=20523113
i am heading out....both TDA accts down so i may as well go outside! :) happy friday
OH NO !!! It means I'll have more than the normal amount of crazies to deal with at work !!!
All areas of communication are affected, especially in matters related to the family, business, particularly home business, travel, domestic relationships and real estate purchases in general.
more then you every wanted to know about....
Mercury in Retrograde ....
At 23:41 UT (Universal Time), just before midnight on June 15, 2007, Mercury, the cosmic trickster, turns retrograde in Cancer, the sign of the Crab, sending communications, travel, appointments, mail and the www into a general snarlup! It's another of those tricky time zone issues, as in places East of Greenwich (Europe; Asia; Africa; Australia; New Zealand) it happens on the 16th! This awkward period begins a few days before the actual turning point (as Mercury slows) and lasts for three weeks or so, until July 10, when the Winged Messenger reaches his direct station. At this time he halts and begins his return to direct motion through the zodiac.
Everything finally straightens out on July 24, as he passes the point where he first turned retrograde. Mercury turns retrograde three times a year, as a rule, but the effects of each period differ, according to the sign in which it happens (see box for Retrograde Periods in 2007).
A planet is described as retrograde when it appears to be moving backwards through the zodiac. According to modern science, this traditional concept arises in the illusory planetary motion created by the orbital rotation of the earth, with relation to other planets in our solar system. Planets are never actually retrograde or stationary, they just seem that way, due to this cosmic shadow-play.
Retrograde periods, although often problematic for us earthlings, are not particularly uncommon. Each planet retrogrades, except the Sun and Moon. Although a powerful astrological influence, Mercury is quite a small planet that travels at a relatively fast speed through the zodiac. Despite being the closest planet in our solar system to the Sun, it is not always in the same sign as the Sun (for example, this year Mercury turns in Cancer while the Sun is in Gemini and is still in Cancer when the Sun has moved right through Cancer and on into Leo).
Fated Events
As a rule, retrograde planets presage a period of seemingly inevitable or fated events that relate to their sphere of influence. They present us with a series of events over which we seem to have little or no control, relating especially to the sign in which the retrogradation occurs. For example, Mercury retrograde in Pisces presents quite different sets of circumstances from those generated when it retrogrades into Aquarius.
A retrograde period is best seen as a cycle, beginning when the planet begins to slow to a halt before travelling backwards through the zodiac and ending when the planet returns to the point where it first paused. However, during the cycle, the planet's energy is most powerful (and more likely to generate critical events of universal importance) when the planet makes a station: appearing motionless in the sky.
These stationary periods occur near the beginning of the cycle (when the planet first halts as it prepares to move backwards) and midway through the cycle when the retrograde planet slows to a stop before moving forward again. The "direct station" (when the planet halts before moving forward again) is the most powerful and can be used for maximum benefit.
Some astrologers consider that the "Mercury Shadow" begins some three weeks before the actual retro station (when Mercury passes the point of direct station for the first time), but I am more inclined to think that the really noticeable peculiarities begin when Mercury slows significantly, a few days before the retro station. This period of "Mercury Shadow" extends to the Return date, some three weeks after the direct station. Bear this in mind, because experience shows that the effects of the retro period are still marked during the "shadow" phase. Some of the most characteristic annoyances often occur just after Mercury makes the direct station, while he is crawling forward before picking up speed.
What does Mercury affect?
In general, Mercury rules thinking and perception, processing and disseminating information and all means of communication, commerce, education and transportation. By extension, Mercury rules people who work in these areas, especially people who work with their minds or their wits: writers and orators, commentators and critics, gossips and spin doctors, teachers, travellers, tricksters and thieves.
Mercury retrograde gives rise to personal misunderstandings; flawed, disrupted, or delayed communications, negotiations and trade; glitches and breakdowns with phones, computers, cars, buses, and trains. And all of these problems usually arise because some crucial piece of information, or component, has gone astray, or awry.
It is therefore not wise to make important decisions while Mercury is retrograde, since it is very likely that these decisions will be clouded by misinformation, poor communication and careless thinking. Mercury is all about mental clarity and the power of the mind, so when Mercury is retrograde, these intellectual characteristics tend to be less acute than usual, as the critical faculties are dimmed. Make sure you pay attention to the small print!
The Key Issue
The key issue here is one of focus. Mercury's retro phase tends to bring unforeseen changes and blockages, but the aggravation and frustration that many of us experience during these periods is often due to our own inability to roll with the punches. Is this due to our ego-fixation? Mercury sets out to restructure our thinking processes and for many of us this is painful and frustrating. Moreover, these experiences reveal flaws in our internal organisation as well as our external planning, which can make us feel foolish and inadequate.
Mercury retrograde, like any cosmic aspect, affects people differently, depending on where it hits their personal charts. Some people actually prosper under a retro Mercury, especially if Mercury is retrograde but otherwise well-aspected in their birth charts. It is also a time when matters begun under a previous retro period will come to fruition, or completion as the case may be. Firm decisions that have been previously made when Mercury is travelling normally through the zodiac may be implemented or finalised while Mercury is retrograde without too much worry, for experience shows that this can be done without undue problems arising.
Mercury Retrograde in Cancer
When Mercury is retrograde, everyone's thinking is more introspective and we tend to think about issues and concerns which relate to the sign involved. With Mercury retrograde in Cancer, people with this sign prominent in their charts will be especially prone to such introspection. There is little choice but to reconsider our personal views and opinions about life. We receive, however, an opportunity to gain insight into our own ego.
Mercury retro in Cancer creates mental and emotional confusion, combined with memory lapses. People will love praise and flattery, yet easily take offence. Home businesses are particularly susceptible to communication breakdown. Mercury in Cancer is very emotional and sensitive, so people will find it difficult to separate their thoughts from their feelings, being particularly subject to absorbing the ideas and thoughts of people in the close environment. People will seem to be much more moody than usual and emotional problems will give rise to digestive upsets. The big temptation will be to overeat to compensate for emotional disturbances.
All areas of communication are affected, especially in matters related to the family, business, particularly home business, travel, domestic relationships and real estate purchases in general. This period brings travel snafus and missed appointments of all kinds. Documents can go astray. Be sure to carry a diary and refer to it often.
lol..2 true, started the day by having no online access at all till an hour after the bell..no matter anyway..with all the MMM driving volume out of the pennies its better to take a break.
Ameritrade is down - Mercury is in retrograde! lmao
ILNS - Intellect Neurosciences, Inc. Common Stock Commences Trading Under Symbol 'ILNS'
NASD has approved quotation of Intellect's common stock on OTC Bulletin Board
Jun 14, 2007 9:35:00 AM
NEW YORK, June 14 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that the NASD has approved the quotation of its common stock on the Over the Counter Bulletin Board under the symbol "ILNS". Trading commenced on June 13, 2007, with a closing price on that day of $2.80 per share. The Company has approximately 30 million primary outstanding shares.
"We are proud to join the ranks of publicly traded biotech companies, and are delighted to provide the investing public the opportunity to participate in our exciting journey to develop innovative solutions to Alzheimer's disease, one of today's most challenging therapeutic areas," commented Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer. "This achievement allows us to expand our financing alternatives and access the requisite capital needed to progress our ambitious clinical development plans."
"We are gratified that our shares are quoted on the OTC Bulletin Board, thus providing liquidity for investors in our common stock and providing us with additional financial flexibility," commented Intellect's President and CFO, Elliot M. Maza.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease. Recently, the Company successfully completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that is a potentially disease modifying drug for Alzheimer's disease and other important medical indications. Audited data from these clinical trials, conducted in The Netherlands, is expected to be available shortly.
The Company also has broad proprietary immunotherapy platforms with patented drug candidates for both passive and active immunization against Alzheimer's disease. Its pioneering activities in the field have placed it at the forefront of the attack against this devastating disease. Intellect's patent estate contains issued and pending claims in Europe, Japan, the US and other major territories, providing a formidable strategic advantage.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the toxic accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are over 24 million people suffering from Alzheimer's disease in the major markets worldwide with the number projected to increase to 80 million by 2040 as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective disease modifying drugs.
For additional information, please visit http://www.intellectns.com
SOURCE Intellect Neurosciences, Inc.
----------------------------------------------
Elliot Maza
President & Chief Financial Officer of Intellect Neurosciences
Inc.
+1-212-448-9300
FMGL changing symbol for some reason...its a lightly traded shell on daily list today
will be FNGL
CBPC - China Biopharma Signed LOI to Acquire All the Interest of a Chinese Regional Pharmaceutical Distribution Company
- Acquisition Would Bring $3 Million Additional Revenue in 2007
Jun 12, 2007 8:46:00 AM
PRINCETON, N.J., June 12 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced that its China operation subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd. ("HCBP") has signed a letter of intent to acquire 100% of the interest of Beijing Tiancheng Haixin Pharmaceutical Co., Ltd. ("BTHP"), a regional distribution company headquartered in Beijing, China. The company believes that the acquisition will expand CBPC's presence in the Northern region of China with BTHP's well established distribution licenses and logistic facilities. The acquisition would also add direct distribution channels into 175 hospitals in the region. Currently, the main customers of HCBP are local Chinese CDCs. This acquisition would bring $3 million additional revenue in 2007 and $6 million in 2008 into HCBP's current revenue source.
According to the letter of intent, HCBP would use its internal available resource to complete the acquisition. "We are very happy to see this acquisition could take place," said Peter Wang, CEO of China Biopharma, Inc. "It would significantly improve our current distribution platforms and widen our product lines in the near future."
About China Biopharma Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the Company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net .
CONTACT:
China Biopharma, Inc.
Attn.: George Ji
Tel: +1 (609) 651-8588
ir@chinabiopharma.net
www.chinabiopharma.net
Safe Harbor Statement
Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
SOURCE China Biopharma, Inc.
----------------------------------------------
George Ji of China Biopharma
Inc.
+1-609-651-8588
ir@chinabiopharma.net
re: CTUV
was CVNE before a 3/1 f/s
last .80
As a result of the stock split, the Company now has 37,468,926 shares of common stock outstanding.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 8, 2007
Date of Report (Date of earliest event reported)
CENTRUS VENTURES INC.
(Exact name of registrant as specified in its charter)
NEVADA 000-52391 20-4178322
(State or other jurisdiction of (Commission File (IRS Employer Identification No.)
incorporation) Number)
810 Peace Portal Drive, Suite 200
Blaine, Washington 98230
(Address of principal executive offices) (Zip Code)
(360) 318-3788
Registrant's telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
--------------------------------------------------------------------------------
ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.
Effective June 8, 2007, Centrus Ventures Inc. (the "Company") amended its Articles of Incorporation in accordance with Article 78.207 of Chapter 78 of the Nevada Revised Statutes by splitting its issued and authorized capital on a 3-for-1 basis. Accordingly, the Company’s authorized capital of common stock has been increased from 100,000,000 shares to 300,000,000 shares of common stock, $0.001 par value per share, and the Company’s issued and outstanding shares were increased on a 3-for-1 basis such that each shareholder now holds three shares for each one share previously held.
As a result of the stock split, the Company now has 37,468,926 shares of common stock outstanding.
A copy of the Company’s file-stamped Certificate of Change to its authorized capital is attached as an exhibit to this report.
ITEM 7.01 REGULATION FD DISCLOSURE
NEW STOCK SYMBOL
As a result of the 3-for-1 stock split, the Company’s trading symbol has been changed to “CTUV.” effective June 8, 2007. As this is a true stock split, shareholders will need to surrender their old pre-split certificates to obtain a new certificate representing the post-split shares. Shareholders of record as of June 8, 2007 are entitled to redeem their existing share certificates for a new certificate reflecting the new number of shares. A letter of transmittal for that purpose will be sent to the Company’s shareholders.
PRIVATE PLACEMENT FINANCINGS
On June 11, 2007, the Board of Directors has approved two concurrent private placements as follows:
U.S. PRIVATE PLACEMENT
The Company’s Directors have approved a private placement offering of up to 1,000,000 shares (the “Shares”) at a price of $1.00 US per Share (the “US Offering”).
The offering will be made in the United States to persons who are accredited investors as defined in Regulation D of the Securities Act of 1933.
The Company will pay a commission of 10% to licensed brokers or investment dealers or other qualified finders (the “Brokers”) in connection with the US Offering and issue to the Brokers warrants (the “Brokers Warrants”) entitling them to purchase up to 10% of the number of Shares placed by them at a price of $1.25 US per Share for a period of two years from closing of the US Offering.
2
--------------------------------------------------------------------------------
The Company will grant piggyback registration rights in respect of the shares comprising the US Offering and the shares to be issued upon exercise of the Brokers Warrants, such registration rights to be subject to any restrictions that may be required by any underwriter of any offering in respect of which such registration rights may apply.
FOREIGN PRIVATE PLACEMENT
The Company’s Directors have also approved a concurrent private placement offering of up to 5,000,000 Shares to persons who are not “U.S. Persons” as defined in Regulation S of the Securities Act of 1933 (the “Foreign Offering”).
The Company will pay a commission of 10% to licensed brokers or investment dealers or other qualified finders (the “Brokers”) in connection with the Foreign Offering and issue to the Brokers warrants (the “Brokers Warrants”) entitling them to purchase up to 10% of the number of Shares placed by them at a price of $1.25 US per Share for a period of two years from closing of the Foreign Offering.
The Company will grant piggyback registration rights in respect of the shares comprising the Foreign Offering and the shares to be issued upon exercise of the Brokers Warrants, such registration rights to be subject to any restrictions that may be required by any underwriter of any offering in respect of which such registration rights may apply.
The proceeds of the U.S. Private Placement and the Foreign Private Placement offerings will be used to fund the Company’s proposed merger candidate Royal Mines Inc. and development and for general corporate purposes. There is no assurance that the U.S. Private Placement or the Foreign Private Placement offerings or any part of them will be completed. There is no assurance that the Company will enter into a formal merger agreement or complete a merger with Royal Mines Inc.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
Exhibit Number Description of Exhibit
3.1 Certificate of Change Pursuant to NRS 78.209 increasing the authorized capital of common stock to 300,000,000 shares, par value $0.001 per share.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
3
--------------------------------------------------------------------------------
CENTRUS VENTURES INC.
Date: June 11, 2007
By: /s/ Kevin B. Epp
KEVIN B. EPP, PRESIDENT
4
PKPTE - YFonGlobal Announces Intent to Trade on the OTC Bulletin Board
Premier Social Network Enabler, YFonGlobal, LLC, has Reached Agreement to Reverse Merge into with PacketPort.com, Inc. (NASD, OTC, PKPTE)
Jun 12, 2007 7:55:00 AM
Copyright Business Wire 2007
WASHINGTON--(BUSINESS WIRE)--
YFonGlobal,LLC, a leading social network enabler, announced the signing of a letter of intent with PacketPort.com, Inc., a Nevada corporation, that is currently a public corporation trading on the Over-The-Counter (OTC) Bulletin Board under the ticker symbol ("PKPTE"). Under the terms of the Letter of Intent, YFonGlobal will consummate, a reverse merger into PacketPort.com, Inc. that, upon completion, will result in YFonGlobal, LLC becoming a publicly traded corporation listed on the over the counter bulletin board. This is a non binding Letter of Intent that could lead to a transaction that must be endorsed by the respective boards of directors and shareholders prior to consummation. An appropriate Form 8(K) was filed with the Securities and Exchange Commission by PacketPort.com, Inc. on Friday, June 8, 2007.
Working closely with Source Capital Group (SCG) in Westport, CT, a leading middle market investment bank, YFonGlobal expects to raise between $5-10 million subject to completion of the reverse merger. YFonGlobal has over $8 million in contract backlog and seeks to build-out delivery and sales support services to meet substantial demand for this emerging category. Recent competitive wins against MySpace and FaceBook, have demonstrated strong demand for the feature-rich social network application offered by YFonGlobal, and marketed under the trade name, wyndstorm(TM).
"With access to public financial markets, we have a tremendous opportunity to grow our social network solutions. This financing is critical to continue our growth, execute our strategy, and maintain our leadership position in this space," said Marian Sabety, President and CEO of YFonGlobal. "Capital will be used to expand our sales force and meet the explosive demand posed by both domestic and global interest in our social network offerings. We will also expand our end-to-end customized social network applications for B2B and B2C online marketing programs. This transaction and related funding positions us to offer one-stop social network set-up, customization, and ongoing program management."
On June 14th, YFonGlobal is launching a 1.6 million subscriber social network for Golden Key, an association of international students seeking a private community for online collaboration. YFonGlobal beat MySpace and FaceBook in winning the contract to host this community based on meeting tailoring requirements that included security from non-members, blocking inappropriate content, controlled advertising, and free buddy-buddy calling between members. YFonGlobal hosts a proprietary business software application that provides online collaboration, integrated voice over IP (VoIP) calling services and encryption. Unlike MySpace and FaceBook, YFonGlobal allows clients to offer customized, private, and safe communities with controlled advertising, dramatically expanding the market for these applications to address privacy and security concerns.
About YFonGlobal, LLC
YFonGlobal, a Washington D.C.-based company, provides turnkey social networking solutions tightly integrated with voice-over-Internet Protocol (VoIP) network solutions for affinity marketing leaders. Using wyndstorm(TM) hosted application, clients can rapidly tailor and privately brand custom social networks by selecting from over 52 pre-built modules. wyndstorm provides search, security, click-to-call, consumer-posted content licensing, and other value-add features that provide high value collaboration and programming for private brand marketing. For more information about YFonGlobal, LLC, visit www.yfonglobal.com.
Source: YFonGlobal, LLC
----------------------------------------------
YFonGlobal
LLC
Nancy Rose Senich
703-442-0080
pr@wyndstorm.com
BVIC - Athersys Raises $65 Million in Concurrent Reverse Merger and Private Equity Offering
Jun 11, 2007 2:30:00 PM
CLEVELAND, June 11 /PRNewswire/ -- Athersys, Inc., a privately held biotechnology company, has announced that it has successfully completed a reverse merger with BTHC VI, Inc. (OTC Bulletin Board: BVIC). BTHC plans to change its name to Athersys, Inc. as soon as practical after all applicable requirements can be satisfied. In conjunction with the merger, BTHC has completed a private placement, resulting in gross proceeds of $65 million.
The merger transaction was completed by the merger of a wholly-owned subsidiary of BTHC and Athersys, with Athersys remaining as the surviving company and a wholly-owned subsidiary of BTHC. As a result of the merger, Athersys constitutes BTHC's sole business. The officers and directors of Athersys have replaced all of the officers and directors of BTHC, the company will retain all Athersys employees, and the company will maintain its principal operations in Cleveland, Ohio.
As part of the transaction, BTHC sold 13 million shares of common stock at $5.00 per share to institutional and other accredited investors. The company also issued to the investors warrants to purchase additional shares of common stock with an exercise price of $6.00 per share. Cowen and Company, LLC and National Securities Corporation acted as co-placement agents for the private placement.
Radius Ventures led the financing, with significant participation from OrbiMed Advisors, RA Capital Management, Accipiter Capital Management LLC, Hambrecht & Quist Capital Management LLC, MPM BioEquities, and Pappas Ventures, as well as a number of other well-known healthcare institutional investors. Joining the board at the closing of the transaction will be Jordan Davis, Managing Partner of Radius, Mike Sheffery, General Partner of OrbiMed, and Floyd D. Loop, M.D., Venture Partner at Radius. Proceeds from the financing will be used primarily to fund the continued clinical development of Athersys' obesity program, including its lead candidate, ATHX-105, and its non-embryonic stem cell product, MultiStem(R), to treat patients for certain cardiovascular disorders, bone marrow transplantation support, and other disease indications, certain pre-clinical development activities, debt repayment, working capital and general corporate purposes.
"We are excited to invest in Athersys in connection with its debut as a publicly-traded company," said Jordan Davis. "In particular, we are attracted to Athersys' "fast follower" approach and its focus on developing products that have "best-in-class" potential in multibillion dollar markets."
The securities issued by BTHC have not been registered under the Securities Act of 1933 or any state securities laws. Therefore, such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and any applicable state securities laws. This press release does not constitute an offer to purchase any securities or a solicitation of an offer to sell any securities.
About Athersys
Athersys is a biopharmaceutical and regenerative medicine company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of its proprietary technologies, it has established a pipeline of therapeutic product development programs in multiple disease areas. Athersys' lead product candidate, ATHX-105, a highly selective agonist of the serotonin receptor 5HT2c, a validated molecular target located in the region of the brain that regulates appetite and food intake. Compounds acting on this target have been shown to reduce appetite and result in weight loss in animal models and humans. In addition to its lead product candidate, the company is developing novel pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary capabilities and technologies including Random Activation of Gene Expression (RAGE).
Athersys is developing MultiStem(R) to treat patients for certain cardiovascular disorders, stroke, bone marrow transplantation and oncology support, as well as other disease indications. MultiStem is a patented stem cell product that is based on a special class of adult-derived stem cells known as Multi-Potent Adult Progenitor Cells (MAPC). MultiStem may be isolated from the bone marrow and other non-embryonic tissue sources, can be routinely expanded to create large product inventories, and is being developed for off- the-shelf treatment of patients. Athersys is a founding member of the Center for Stem Cell and Regenerative Medicine based in Cleveland, Ohio, with the Cleveland Clinic, University Hospitals and Case Western Reserve University.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, including the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: the possibility of delays in, adverse results of, and excessive costs of the development process; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Athersys, Inc.
----------------------------------------------
William (B.J.) Lehmann
J.D.
President and Chief Operating Officer
bjlehmann@athersys.com
or Laura Campbell
Vice President of Finance
lcampbell@athersys.com
of Athersys
Inc.
+1-216-431-9900
BPMT - Value Providers Inc, the Largest Manufacturer of Durable Medical Equipment Sold in the U.S., Makes Substantial Investment Into BioPharmetics, Inc.
Investment Expected to Increase BioPharmetics Sales to Over $20 Million per Year
Jun 11, 2007 8:31:00 AM
SUN VALLEY, CA -- (MARKETWIRE) -- 06/11/07 -- BioPharmetics, Inc. (PINKSHEETS: BPMT) announced that Value Providers Inc, one of the largest manufacturers of Durable Medical Equipment sold in the U.S., has made a significant investment into BioPharmetics.
Under the terms of this investment, BioPharmetics will now become the exclusive distributor on all current and future VPI product lines to include Medicare reimbursed products such as wheelchairs, walkers, and various other home and healthcare products throughout the U.S., its territories and the United Kingdom. In addition, BioPharmetics will assume full responsibility to manage sales through a network of 500 dealers throughout the U.S.
The company issued the following statement, "Through this investment into BioPharmetics, Inc., the company now has a dealer network of over 500 throughout the U.S. with manufacturer pricing in place to assist our dealers in best pricing to deepen their market share and assist us in reaching our projected sales goals of close to $20 million over the next 12 months. In addition, as competitive bidding through Medicare is finalized over the next 5 months, we'll be in a prime position to capture a significant portion of the bids through the dealer network. This could have an impact on our revenues to potentially see the company reach close to $100 million in sales over the next 36 months," stated Mr. Paul D. Lisenby, CEO of BioPharmetics, Inc.
For dealers looking for guaranteed lowest product pricing for competitive bidding, please call 877-819-8701 XT 245
About BioPharmetics, Inc. (PINKSHEETS: BPMT) www.biopharmetics.com
BioPharmetics, Inc. provides quality durable medical equipment, diabetic supplies, and health, beauty, and anti-aging products to customers in the U.S., Canada, and over 23 countries throughout the world. The company operates three separate divisions: Biotechnology, Pharmaceuticals, and Cosmetics. The pharmaceutical division, our largest, distributes medical equipment and diabetes supplies, dispenses physician-prescribed medications through our pharmacy partners, as well as working closely with our dealer network, health care companies, and managed care facilities to provide superior pricing and customer support for Medicare, Medi-Cal, Medicaid and private insurance reimbursement programs.
Safe Harbor
This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.
Contact:
FutureTechIR for BioPharmetics
Investor Relations
(727) 417-9338
Hedge funds JANA Partners and S.A.C. Capital Advisors, which control about 8.4 percent of TD Ameritrade, have told the company it should merge with either of its rivals, E*Trade Financial or Charles Schwab Corp. to boost shareholder value.
lil about...SAC Capital / Steven A. Cohen
SAC Capital Advisors in a harsh spotlight
March 27, 2006
The secretive hedge fund SAC Capital Advisors, run by Stephen Cohen, is taking some big media hits. 60 Minutes ran a lengthy piece on its battle with Biovail, which has sued the hedge fund and is more than willing to discuss the issues publicly. Its take is that SAC conspired with a so-called independent research outfit to produce damaging reports and then pushed the firm to delay release of the report so it could build a short position.
How Does Steve Cohen Do It?
Your article about "Stevie" Cohen was infuriating ("The most powerful trader on Wall Street," Cover Story, July 21). Clearly, the markets are stacked in favor of people like SAC Capital Advisors founder Steven A. Cohen, who (according to your writers) trades on special, nonpublic, material information that is unavailable to the public.
Geoffrey Batrouney
New Rochelle, N.Y.
You note that SAC Capital Advisors pays full commissions and thereby receives analysts' recommendations ahead of the general public. How is this different from one of his traders acting on information from his analyst wife before it is made public?
Ted Levin
Grant, Koehler & Levin Ltd.
Seattle
Editor's note: The writer is a partner in an investment advisory firm.
"The most powerful trader on Wall Street" did not make it clear just how effective the alleged "three aggressive tactics" have been for SAC Capital Advisors, and you neglected to mention the extent to which SAC uses the legal practice of "front-calling" (not to be confused with the illegal practice of "front-running"). I suspect that such tactics would not add more than a few basis or percentage points to long-term returns, and that most of SAC's returns have been caused by other factors.
Charlie Stromeyer Jr.
Concord, Mass.
AUGUST 11, 2003
Hedge Funds Rattle Ameritrade's Cage
By Laurie Kulikowski
TheStreet.com Staff Reporter
6/8/2007 11:47 AM EDT
Two activist hedge funds say the time for TD Ameritrade (AMTD - Cramer's Take - Stockpickr - Rating) to sell itself is now.
The funds, S.A.C. Capital Advisors and Jana Partners, have taken an 8.4% stake in the Omaha, Neb., online broker. They called Friday for the second time in a week on Ameritrade to sell itself to either Charles Schwab (SCHW - Cramer's Take - Stockpickr - Rating) or E*Trade Financial (ETFC - Cramer's Take - Stockpickr - Rating).
"Quite frankly, we fail to see how an unbiased review could leave any doubt that the 'right time' to pursue such a combination is now," the hedge funds say in a letter to Ameritrade and accompanying press release. "This is particularly true given that the company has now completed its integration of TD Waterhouse and that the currently favorable industry environment for transactions will most assuredly not last forever, creating the real risk that if the board continues to wait it will have permanently squandered this opportunity."
The comments from S.A.C. and Jana come a day after Ameritrade chief Joe Moglia told investors that the company would be "deliberate" in pursuing its growth strategy.
Shares of all three online brokers rose on the news. TD Ameritrade's stock rose 41 cents, or 2%, to $20.41. Shares of E*Trade rose 37 cents, or 1.5%, to $24.55. Schwab, which has said it's not interested in buying Ameritrade, rose 10 cents to $21.32.
S.A.C. and Jana first suggested Tuesday that TD Ameritrade "pursue a business combination with one of its industry peers."
In Friday's letter, S.A.C. and Jana also reiterated that they see "glaring conflicts of interest" in TD Ameritrade's dealings with its largest shareholder, TD Bank (TD - Cramer's Take - Stockpickr - Rating). The funds say TD Bank won't pursue a sale of Ameritrade because of "its reliance on the company to advance its own business strategy."
They suggested that TD Ameritrade use a committee of outside directors that is "free from influence" of TD Bank to review possible merger considerations.
Moglia said Thursday at a Sandler O'Neill & Partners Conference that the company regularly reviews its M&A strategy and cautioned that investors should not limit the company's next acquisition to just an online broker.
The company has "an intense focus on our business plan and along with that really looking hard to make sure we are looking at a number of opportunities in the marketplace -- not just what's going on in online brokerage," Moglia said. "As we get more into the asset gathering space perhaps we're supposed to be more creative with regard to where we might look for strategic opportunities."
MAXC - Maxco, Inc. Declares Dividend of $2.00 Per Share on Its Common Stock
May 25, 2007 4:01:00 PM
GRAND LEDGE, Mich., May 25 /PRNewswire-FirstCall/ -- Maxco, Inc. (the "Company") (Pink Sheets: MAXC) has declared a cash dividend of $2.00 per share, payable June 29, 2007, to common shareholders of record as of June 20, 2007.
Maxco's President and CEO Max A. Coon, stated "Historically Maxco has not paid dividends on its common stock. Due to the cash flow from the sale of our former 100% owned subsidiary, Atmosphere Annealing, Inc., Maxco's Board felt that it would be in the best interest of Maxco's shareholders to declare this dividend."
Maxco has investments in real estate and investments representing less than majority interests in the following businesses: a developer, manufacturer and marketer of microprocessor-based process monitoring and inspection systems for use in industrial manufacturing environments; and an energy-related business.
SOURCE Maxco, Inc.
----------------------------------------------
Max A. Coon
CEO of Maxco
Inc.
+1-517-627-1734
MAXC - Maxco, Inc. Files Form 15 With Securities And Exchange Commission
Jun 8, 2007 11:12:00 AM
GRAND LEDGE, Mich., June 8 /PRNewswire-FirstCall/ -- Maxco, Inc. (the "Company") (Pink Sheets: MAXC) announced today the filing of a Form 15 with the Securities and Exchange Commission (the "SEC"). Maxco filed the Form 15 with the SEC in order to effect a termination of registration of its common stock and Series Three preferred stock under the Securities Exchange Act of 1934.
Under the SEC'S rule, a company with fewer than 300 shareholders of record may voluntarily terminate the registration of its securities by filing a Form 15 pursuant to which it certifies that the number of record holders of the class of securities registered is less than 300. Maxco currently has fewer than 300 common shareholders of record and has no Series Three preferred shareholders. Registration of the securities will not terminate until 90 days after the filing of the Form 15; however, the Company's duty to file periodic reports such as 10Qs and 10Ks is suspended immediately upon filing the Form 15. The Company's shares are quoted in the Pink Sheets quotations system.
Maxco is taking action for a number of reasons, foremost of which is the cost associated with being a SEC reporting company is substantial for a company its size, especially in light of the additional costs associated with compliance with Sarbanes Oxley. The Maxco Board of Directors believes that the high cost of Sarbanes Oxley compliance far exceeds its benefit to Maxco shareholders. Other factors considered as part of this decision were: (i) the Company's common stock is very thinly traded, (ii) the Company foresees no capital raising benefits from being a reporting company.
Max A. Coon, President and Chief Executive Officer of Maxco, Inc., stated that it is the Company's intention to provide its shareholders annual audited financial information as well as to make available unaudited quarterly financial information (copies will be sent to shareholders upon request).
Maxco has investments in real estate and investments representing less than majority interests in the following businesses: a developer, manufacturer and marketer of microprocessor-based process monitoring and inspection systems for use in industrial manufacturing environments; and an energy-related business.
SOURCE Maxco, Inc.
----------------------------------------------
Max A. Coon
CEO of Maxco
Inc.
+1-517-627-1734
CMHM - Conmed Healthcare Management, Inc. Announces Two New Service Contracts Potentially Totaling Approximately $17.1 Million
Jun 8, 2007 9:06:00 AM
Copyright Business Wire 2007
LA PLATA, Md.--(BUSINESS WIRE)--
Conmed Healthcare Management, Inc. (OTCBB:CMHM) announced the signing of two new service contracts potentially generating approximately $17.1 million in total revenue over the next five years.
The first contract with the county of Henrico, Virginia (Richmond) is to provide medical staffing services from June 1, 2007 to May 31, 2008 and may be renewed for four additional one year periods upon mutual agreement between the County and Conmed. The annual fee is approximately $2.9 million for the first full year of the agreement and $14.2 million if all of the four one year renewal periods are exercised.
The second contract with Jackson County, Oregon (Medford) is a full risk contract to provide medical staffing, pharmaceuticals, hospitalization, dentistry, and other specialty care plus related services to the county's adult detention center, the juvenile service center and community justice transition center (work release). The contract extends from May 15, 2007 to June 30, 2010 with an annual fee of approximately $0.9 million and $2.9 million for the full term of the contract.
Richard W. Turner, President and CEO of Conmed stated, "We are extremely pleased to have won both of these new contracts. The contract with the County of Henrico, Virginia is our second contract in the state and is located adjacent to the state capitol of Richmond. The county has two detention centers with an average inmate population of approximately 1,200. The Jackson County contract is our first contract in the state of Oregon and strengthens our expansion into the Pacific Northwest. The contract covers approximately 400 individuals, which includes the first juvenile service center serviced by Conmed Healthcare Management."
About Conmed
Conmed has provided correctional healthcare services since 1984, beginning in the state of Maryland, and currently services 20 detention centers and facilities at the county level throughout the United States. Conmed's services have expanded to include mental health, pharmacy and out-of-facility healthcare expenses.
Forward Looking Statements
This press release may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties including those contained in its public filings. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the company's control including, without limitation, the Company's ability to increase revenue and to continue to obtain contract renewals and extensions.)
Source: Conmed Healthcare Management, Inc.
----------------------------------------------
Conmed Healthcare Management
Inc.
Thomas W. Fry
301-609-8460
Chief Financial Officer
tfry@conmed-inc.com
In addition, the Company's principal stockholder, Kevin B. Epp, would agree to surrender for cancellation to the Company 23,500,000 (post-split) shares of the Company's common stock held by him.
As a result of the proposed transactions upon completion of the proposed merger, the Company would have approximately 45,700,000 (post-split) shares of common stock issued and outstanding.
CVNE,
on daily list 3/1 f/s, also...
from recent pr...
(negotiating a possible merger)
Centrus Ventures Inc. Announces Stock Split
Wednesday May 30, 8:17 pm ET
BLAINE, WA--(MARKET WIRE)--May 30, 2007 -- Centrus Ventures Inc. (OTC BB:CVNE.OB - News) (the "Company") announced today that its director has approved a 3-for-1 stock split of its authorized and issued shares of common stock. The split is expected to be effective on June 8, 2007.
The Company also announced that it is negotiating a possible merger with Royal Mines Inc., a Nevada corporation engaged in mineral property exploration and development in Nevada and Arizona. The parties anticipate that the merger will be accomplished on a basis that will result in the existing stockholders of Royal Mines Inc. receiving approximately 31,700,000 (post-split) shares of the merged entity. In addition, the Company's principal stockholder, Kevin B. Epp, would agree to surrender for cancellation to the Company 23,500,000 (post-split) shares of the Company's common stock held by him.
As a result of the proposed transactions upon completion of the proposed merger, the Company would have approximately 45,700,000 (post-split) shares of common stock issued and outstanding. The Company has instructed its legal counsel to prepare a formal agreement for the merger. There is no assurance that a formal agreement will be executed or the merger completed.
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors including risks disclosed in the Company's periodic filings with US securities regulators. When used in this news release, the words such as "proposed," "could," "plan," "estimate," "expect," "intend," "may," "potential," "should," and similar expressions, are forward-looking statements. In particular there is no assurance that a formal merger agreement will be executed or that the proposed merger and share cancellation will be completed.
Contact:
Contact:
Carol Kinney
Centrus Ventures Inc.
Suite 200, 810 Peace Portal Drive
Blaine, WA 98230
Telephone: (360) 318-3788
--------------------------------------------------------------------------------
Source: Centrus Ventures Inc.
interesting...it appears that you can buy ANTISOMA PLC under the ticker AIOAF (a pinky) or an ADR for 20 shares under the ticker ATSMY that trades on the OTCBB...if I am understanding this correctly...which might be a stretch
AIOAF - Antisoma receives USD 75 million following successful completion of ASA404 licensing agreement
London, UK, 7 June 2007: Antisoma plc (LSE:ASM, US OTC: ATSMY) announces that it has received the first scheduled payment of USD 75 million from Novartis under the recently announced licensing agreement for ASA404 (formerly AS1404).
The payment was triggered by completion of the licensing agreement following notification from the competent US authorities regarding compliance with the provisions of the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Enquiries:
Daniel Elger, Director of Communications, Antisoma plc
+44 (0)20 8799 8200
Antisoma disclaimer
Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.
Background on ASA404
ASA404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. CRUK had supported two phase I studies in the UK and New Zealand. ASA404 has shown a substantial survival benefit in patients with non-small cell lung cancer when added to paclitaxel-based chemotherapy in a randomised phase II study. Worldwide rights to the drug were licensed to Novartis AG in April 2007.
Background on Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information.
Copyright © Hugin ASA 2007. All rights reserved.
Source: Market Wire (June 7, 2007 - 7:05 AM EDT)
News by QuoteMedia
www.quotemedia.com
no..that does not make me feel any better at all.
me too if it makes you feel better
CNTE to CNEW to DBTB fyi
DBTB - Debut Broadcasting Corporation, Inc. Completes Reverse Merger
Begins Trading Under New Symbol DBTB.OB
Jun 4, 2007 11:02:00 AM
NASHVILLE, Tenn., June 4 /PRNewswire-FirstCall/ -- Debut Broadcasting Corporation, Inc. (Nasdaq: DBTB.OB), a radio broadcasting and syndication company, announced today that it has completed its reverse merger resulting in the company being publicly traded on the NASDAQ Bulletin Board with the new ticker symbol DBTB.OB.
Jim Wood, Chairman of Debut Broadcasting stated, "This listing represents another important milestone for Debut Broadcasting and its shareholders." He continued, "We are pleased to announce that broadcasting veteran Steven Ludwig has joined the Company as CEO and we expect to name two additional members of the management team in coming days."
Debut Broadcasting also announced that it has engaged Catalyst Financial Resources, headed by Marc Robins, CFA, to execute a comprehensive investor awareness campaign aimed at enhancing shareholder value and promoting the visibility of Debut Broadcasting in the financial marketplace.
About Debut Broadcasting Corporation, Inc.
Debut Broadcasting Corporation, Inc. (NASDAQ: DBTB.OB) is a Radio broadcasting company that creates unique synergies between syndicated programming and station ownership. The Company's nine-year old radio syndication company, Impact Radio networks (www.ImpactRadioNetworks.com) distributes programming and services to over 1,100 radio station affiliates in the United States and Canada, reaching over 40 million listeners nationwide each week. Debut Broadcasting is a newly public company trading under the ticker symbol DBTB.OB. For more information about the company please visit www.debutbroadcasting.com or e-mail ir@debutbroadcasting.com.
About Catalyst Financial Resources
Catalyst Financial Resources, LLC is an investor awareness firm assisting small-cap companies gain exposure in the financial community. Founded in 2002 by Marcus Robins, CFA, Catalyst Financial Resources has a proven track record of meeting the needs of both the management and shareholders of small-cap companies. Mr. Robins also founded RedChip Review in 1993 and has been a regular columnist for Forbes magazine. For more information please visit www.catalystresearch.com.
Forward-Looking Statements
This press release may be deemed to contain forward-looking information. Any forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, and products or service line growth, may be significantly and materially impacted by certain risks and uncertainties, including, but not limited to, failure to meet operating objectives or to execute the operating plan, competition, and other economic factors. Additional risks and uncertainties are described in the Company's public filings with the Securities and Exchange Commission.
SOURCE Debut Broadcasting Corporation, Inc.
----------------------------------------------
Press
Marcus Rowe - Director of Marketing and Communications of Debut Broadcasting Corporation
+1-615-301-0001
ext. 104; or Investors
Aimee Boutcher of Catalyst Financial Resources
+1-973-239-2878
re: ACEN...
was over a buck when this news was posted
(teach them I guess...now .31)
ACEN - AC Energy, Potential Victim of Naked Short
May 16, 2007 1:30:00 PM
GARDNERVILLE, NV -- (MARKET WIRE) -- 05/16/07 -- AC Energy (PINKSHEETS: ACEN) addresses the recent volatility in the markets to assure their shareholders that there is no reason for a sudden decrease in price. The company has been notified that they recently been added to Regulation SHO threshold List (http://www.nasdaqtrader.com/aspx/regsho.aspx) which means that there are aggregate fails to deliver at a registered clearing agency of 10,000 shares or more per security which leads the company to believe that they are the potential victims of a Naked Short.
As defined in Rule 203(c)(6) of Regulation SHO, a "threshold security" is any equity security of any issuer that is registered under Section 12 of the Exchange Act, or that is required to file reports under Section 15(d) of the Exchange Act (commonly referred to as reporting securities), where, for five consecutive settlement days:
-- There are aggregate fails to deliver at a registered clearing agency
of 10,000 shares or more per security; and the reported last sale during
normal market hours would value the aggregate fail to deliver position at
$50,000 or more (Rule 32101 Subject to the requirements of NASD Rule 3210)
-- The level of fails is equal to at least one-half of one percent of the
issuer's total shares outstanding; and
-- The security is included on a list published by a self-regulatory
organization (SRO).
A security ceases to be a threshold security if it does not exceed the specified level of fails for five consecutive settlement days. When this occurs, the security becomes subject to mandatory close-out requirements outlined in NASD Rule 3210.
President and Director Mike Dillon states, "The company is in a great position; we have had many inquires in regards to our technology. The company is moving forward to secure more contracts and licensing agreements. The company has engaged Evans & Evans to ensure the company will continue in a profitable position." I invite everyone to view our website www.acenergyinc.com and learn more about the technology and AC Energy.
About AC Energy Inc.
AC Energy is committed to leading the world in research and development of high-quality alternative power sources for cell phones and other small electronics. Our objective is to revolutionize the battery industry by providing consumers with products of unparalleled convenience and efficiency. Through the establishment of select strategic partnerships, AC Energy will maximize its market reach by delivering a commodity of peerless value with virtually unlimited applications in commercial, industrial and military markets.
Forward-Looking Statements:
Note: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation, and the other risk factors listed from time to time in reports filed by AC Energy Corp. with the Securities and Exchange Commission, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operation and Our Stock Price." The forward-looking statements contained in this news release represent judgments of the management of AC Energy Corp. as of the date of this release. AC Energy Corp. and its managers and agents undertake no obligation to publicly update any forward-looking statements.
CONTACT:
AC Energy Inc.
775-782-6739
1528 Hwy 395 N #130
Gardnerville, NV 89410
SGMG - Spectre Gaming Signs Definitive Agreement With Chase Berkshire for the Lease/Purchase of 180 AWP Devices
Jun 1, 2007 9:55:00 AM
MINNEAPOLIS, June 1 /PRNewswire-FirstCall/ -- Spectre Gaming, Inc. (OTC Bulletin Board: SGMG) announced today that it has entered into a capital lease transaction with Chase Berkshire Holdings LLC for the lease/purchase of 180 of the Company's AWP devices for use in Alabama. The agreement is valued at $1.26 million.
D. Bradly Olah, CEO of Spectre stated, "We are pleased to have executed this agreement. Proceeds from the transaction will be applied to outstanding debt to PDS Gaming Corporation, the Company's largest lender. PDS has loaned the Company in excess of $5,000,000 for the purchase of equipment and licenses, and continues to be a supportive partner. With the lease/sale of this equipment, Spectre can transition at a faster pace to its new Titan platform as well as reduce debt."
About Spectre Gaming
Spectre Gaming, Inc. is a provider of proprietary interactive electronic games to the amusement-with-prize (AWP) and charitable gaming markets. The Company designs and develops networks, software and content that provide its customers with a comprehensive gaming system. Learn more at http://www.spectregaming.com .
Risk Factors and Forward-Looking Statements
This news release contains various "forward-looking statements" which are not historical in nature, including but not limited to statements using the terms "may," "expect to," "believe," "should," "anticipate," and other language using a future aspect. Such statements should be viewed as uncertain and should not be relied upon. Although our management believes that the results reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the expectations expressed in such forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include those set forth in the Company's annual report on Form 10-KSB for the year ended December 31, 2006 and in other filings made, from time to time, by the Company with the Securities and Exchange Commission, including the Company's quarterly report filed on May 30, 2007. The forward-looking statements contained herein speak only as of the date when made and the Company does not undertake to update such statements.
SOURCE Spectre Gaming, Inc.
----------------------------------------------
D. Bradly Olah
CEO of Spectre Gaming
+1-612-281-5000
Scalp CALP? (lol) Caliper Life Sciences Receives Significant Patent on Key Biophotonic Imaging Technology
- New Patent Covers Important Classes of Fluorescent and Bioluminescent In Vivo Imaging Methods -
May 31, 2007 8:46:00 AM
HOPKINTON, Mass., May 31 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced its receipt of the Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent covering key methods of in vivo, non-invasive (in living animals, through opaque tissue) imaging of light generated from within mammals. Biophotonic imaging, one of the fastest growing technologies in the life sciences, is rapidly expanding beyond current methods based on light sources genetically encoded in mammals to also include methods based on light sources that are conjugated (or combined) with a biocompatible entity and administered to mammals. Caliper's newly allowed patent covers many of these important developments in biophotonic imaging science.
"In addition to providing researchers with the option to track disease states in an animal without requiring genetic modification of the animal to produce light, the methods covered by the new patent, which encompass a broad range of biophotonic imaging with conjugated probes, are particularly attractive for translation of pre-clinical applications and results into clinical settings," said Kevin Hrusovsky, chief executive officer of Caliper Life Sciences. Mr. Hrusovsky added, "This patent furthers Caliper's leadership position in the biophotonic imaging market. We intend to augment our considerable technology development efforts by also developing biomarkers and innovative conjugate imaging probes and applications for our customers using the technology covered by the patent."
Caliper's existing patent portfolio covers broad methods of in vivo imaging of genetically-produced light generation. The new patent covers the use of conjugates comprising any biocompatible entity and a light source, either fluorescent or bioluminescent. The biocompatible entity can be a cell, microorganism, particle or biological molecule, such as a protein, peptide, or antibody. The data produced from such non-invasive imaging provides researchers with unprecedented insight into events occurring at a molecular level and enables drug developers to gain specific knowledge about potential drug compounds earlier in the drug development process, thus potentially reducing the time to market.
"Caliper's ability to provide license rights to the imaging methods covered by this new patent should further motivate end-users to acquire not only licensing rights but also imaging systems from Caliper. In addition, we believe this new patent will enable us to expand our existing licensing program to a larger group of companies, some of which are already performing non-invasive in vivo imaging with other manufacturers' imaging equipment," said Mr. Hrusovsky, adding that, "We believe revenues from additional imaging products and licenses will begin to materialize in the back end of this year and we are reaffirming our full year revenue guidance of $137 - $143 million which reflects second half pro forma revenue growth of 14% - 23% and GAAP revenue growth of 24% - 34%."
Caliper's family of Xenogen IVIS(R) imaging platforms provides scientists with innovative biophotonic imaging technologies. The IVIS systems deliver real-time in vivo imaging along with high sensitivity, ease of use and exceptional data quality. Caliper has placed over 400 units to date and has recently launched the new Xenogen IVIS Spectrum system to provide state-of-the-art bioluminescence and fluorescence capabilities in a single unit.
The Notice of Allowance corresponds to U.S. patent application serial number 11/143,422 entitled "Non-invasive localization of a light-emitting conjugate in a mammal." A U.S. patent corresponding to the Notice of Allowance will issue when the USPTO receives the requisite issuance fee.
About Caliper Life Sciences
Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its acquisitions of NovaScreen Biosciences and Xenogen Corporation, Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper's products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at http://www.caliperLS.com.
The statements in this press release regarding future events, including statements regarding Caliper's plans to develop imaging probes, biomarkers and applications, Caliper's ability to expand its imaging licensing program based on the allowance of this new patent, and Caliper's belief that its newly allowed patent will have a positive impact on its revenue in 2008 and beyond, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statement as a result of a number of factors, including the risk that unexpected difficulties may be encountered in developing new imaging probes, biomarkers and applications or in obtaining new license agreements with companies already performing biophotonic imaging. Further information on risks faced by Caliper with respect to its microfluidic technology are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2006. This filing is available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release.
Caliper, IVIS, NovaScreen and Xenogen are registered trademarks, and Spectrum is a trademark, of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.
----------------------------------------------
Tom Higgins
Chief Financial Officer of Caliper
+1-508-497-2809; or Stacey Holifield of Schwartz Communications for Caliper
+1-781-684-0770
caliper@schwartz-pr.com
ARYC, Advanced Recycling Sciences, Inc. Signs JV Agreement in Riyadh With Prominent Saudi Arabian Industrial Group Rashid Saad Al-Rashid & Sons
might get interesting
May 30, 2007 1:00:00 PM
IRVINE, CA -- (MARKET WIRE) -- 05/30/07 -- Advanced Recycling Sciences, Inc. (PINKSHEETS: ARYC) ("ARS"), a leader in innovative products and technologies for the tire and rubber recycling industry, announced that Keith Fryer, the ARS President, recently signed a JV agreement in Riyadh, the Saudi Arabian capital, with Rashid Saad Al-Rashid & Sons Co. Limited; represented by Rashid S. Al-Rashid Group Chairman and Yousef R. Al-Rashid Industry Division Manager. Al-Rashid & Sons is a leading Saudi Arabian industrial group, with local operations spanning architectural design & engineering, construction, real estate, farming and local manufacturing with operations located in Riyadh (h/q), and Dammam, Eastern Province.
The JV agreement calls for a direct equity investment by the Al-Rashid Group in the ARS subsidiary Revultec, Inc, based in California, which is presently researching & developing a new and innovative liquid rubber material, suitable for incorporation into rubber industrial products and possibly new tire manufacture. Al-Rashid Group has the option to increase its stake in the venture as key milestones are met by the company. Funds will be employed by ARS to determine the "Proof of Concept" as well as towards company overhead.
The development program will be undertaken in collaboration with the ARS technical partner Applied Power Concepts, Inc., based in Anaheim, California and led by Dr. William A. Farone (President & CEO), whose firm will undertake the material development program and assist ARS will all technical matters related to the project. Dr. Farone has served as President and CEO of APC since 1987 and has 30 years experience in the development of commercial processes from laboratory and pilot plant studies. He has over 90 technical publications in diverse areas including chemistry, electromagnetic phenomena and spectroscopy.
First liquid rubber test material samples are expected to be available for the rubber & tire industry evaluation within 90 days. The rubber industry, Good Year and other leading companies have expressed considerable interest in this exciting new material. Rubber manufacturers and other tire companies will test this material called Tire2Tire(TM)/liquid rubber as soon as it becomes available.
The overall Tires2Tire(TM)/liquid rubber material development program is expected to be completed within 6-months.
About Advanced Recycling Sciences, Inc.
Advanced Recycling Sciences, Inc. provides solutions to alleviate the worldwide environmental dilemma of scrap tires and industrial rubber waste. Through acquisition and development of new technologies, ARS is focused on establishing itself as a leader in the worldwide environmental technology and crumb rubber modified asphalt-paving arenas. For more information, please visit the corporate web site at www.arsciences.com
Safe Harbor Statement:
No stock exchange or Securities Commission has approved nor disapproved the statements in this release. Any statements that are not strictly historical are "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. These statements are subject to a number of risks and uncertainties that may affect actual events or results materially. These include, but are not limited to the Company's ability to obtain adequate financing to further its current and future business strategies; the Company's historical lack of profitability; the effects of business and economic conditions generally; and, other risks associated with a development stage company. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Corporate Contact:
Keith J. Fryer
President and COO
949.260.4728
Mobile: 949.413.9190
Email Contact
www.arsciences.com
yep, specially the ugh part
thnx Chu...I missed NOVC from 9.00
NOW YOU TELL ME!!! UGH!!!
lol !!! you bought one of the chicks ? or all ? better check and see if there high maintenance. Then make your decision !!!
NRLS had some interesting news today & they are going for an AMEX listing as well...
so I should sell???
I would of done it for less and would of gotten much better looking chicks !!! Honestly though, how the hell could you buy that pos after seeing that promo ? But then again, maybe a new twist for the mullet.
and that group was paid $700K for the SPAM; looks like a Russian promo to me but WTFDIK
man oh man, what a racket !
lol...looks like that black petey guy..and he got $700,000
to pump it up.
Check out the latest in spam !!
http://www.investorshub.com/boards/read_msg.asp?message_id=20029875
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |